Immunosuppression following solid organ transplantation (SOT) has a deleterious ef- 
| INTRODUC TI ON
Since the first successful transplant of a kidney in 1954, 1 solid organ transplantation (SOT) has been extended to multiple organ types including liver, heart, pancreas, lung, and small intestine and is increasingly used to treat a variety of end-stage organ diseases. 2, 3 This increase in transplantation volume has been matched by improvements in allograft survival [4] [5] [6] -reflecting both refinements in surgical techniques as well as the incorporation of potent immunosuppressive drug regimens that inhibit T cell-mediated rejection of the transplanted organ. 7, 8 However, these immunosuppressive drugs are nonspecific and hence indiscriminately impair all T cell function. Consequently, recipients of SOTs are vulnerable to a wide array of infections normally controlled by effector T cells, including community-acquired and latent viral infections. [9] [10] [11] [12] [13] [14] Although | 2239
antiviral medications may reduce the incidence and severity of these infections, their long-term use is associated with significant toxicities [15] [16] [17] and for some viruses (eg, BK virus) there are no approved antiviral drugs.
Our group has successfully administered ex vivo expanded virus-
specific T cells (VSTs) to prevent and treat cytomegalovirus (CMV),
Epstein-Barr virus (EBV), adenovirus (AdV), human herpes virus 6 (HHV6), and BK viral infections in allogeneic hematopoietic stem cell transplants (HSCT) recipients. [18] [19] [20] [21] We reasoned that a similar approach might be clinically beneficial in SOT patients. However, whereas rapid tapering of immunosuppression over a 3-6 month period is possible in HSCT recipients, the majority of SOT recipients require more intense and lifelong immunosuppression to prevent allograft rejection. Hence, the goal of the current project was to pro- 
| MATERIAL S AND ME THODS

| Patients and study protocol
This single center prospective study was approved by the Baylor
College of Medicine Institutional Review Board (H36263 and H3342)
and conducted in accordance with the Declaration of Helsinki.
Patients between the ages of 6 months and 20 years, actively listed for liver transplantation at Texas Children's Hospital (TCH), Houston, TX, and able to provide voluntary informed consent/assent (by patient or parent/legal guardian) were eligible for enrollment. At 
| Transplant protocol -immune suppression
Patients received intravenous (IV) methylprednisolone (20 mg/ kg, maximum dose 1 g) at the time of liver transplantation, which was weaned over 5 days to 0.3 mg/kg (max 10 mg/day) of oral prednisone and maintained at this level for 3-6 months thereafter.
Tacrolimus (Prograf) was started on postoperative day 1 to achieve trough levels of 10-12 ng/mL for 1-2 months and then successively tapered to 6-10 ng/mL (months 3 to 6) and 4-6 ng/mL (month 7 onwards (188 copies/mL), and BK (500 copies/mL).
| Cellular immune monitoring
| Peptide libraries
For antigenic stimulation, we used pepmixes (15 mers peptides overlapping by 11 amino acids) spanning the viral antigens Hexon and Penton (Adv), IE1 and pp65 (CMV), EBNA1, LMP2, and BZLF1, LMP1, EBNA3a, EBNA3b, EBNA3c (EBV), VP1, and Large T antigen (BK virus) and U11, U14, and U90 (HHV6), which were purchased from JPT Technologies (Berlin, Germany). Pepmixes were stored in a lyophilized form at −80°C and prior to use were reconstituted in dimethyl sulfoxide (DMSO) (Sigma-Aldrich, St Louis, MO) at a concentration of 200 μg/mL.
| IFNγ ELISpot
ELISpot analysis was used to quantitate the frequency of T cells that 
| Statistical analysis
Results were analyzed using descriptive statistics. Comparisons between the proportion of patients and healthy controls that had response to a given virus were performed using chi-square analysis with Yates' continuity correction. Comparisons of the magnitude of virus-specific T cell responses between patients and healthy controls were performed using a 2-sided Mann-Whitney U-Test.
Wilcoxon signed-rank test was used to compare the difference between matched paired samples. Two-sided P < .05 were considered statistically significant. Statistical tests were performed using GraphPad Prism version 5 for Windows (GraphPad Software, La Jolla, CA, www.graphpad.com).
| RE SULTS
| Patient characteristics and viral immunity pretransplant
We prospectively enrolled 25 children (median 5.5 years; range 0.5-19 years) with end-stage liver disease who were candidates for a liver transplant and actively listed on the United Network for Organ Sharing (UNOS) database (Table S1 ). To first determine whether underlying liver disease had any impact on their immunological fitness, we examined the magnitude and breadth of their pretransplant for all viruses).
| Immunosuppressive characteristics of pediatric liver transplant recipients
Of the 25 liver transplant candidates enrolled in our study, 16 proceeded to transplant and completed at least 1 year of posttransplant follow-up (Table 1 ). Their pretransplant virus-specific T cell responses are shown in Figure S1 . Two patients (pt 2 and pt 14) received rituximab as part of a standard desensitization protocol for patients receiving an ABO-incompatible liver allograft. All patients received initial immunosuppression with the calcineurin inhibitor (CI)
tacrolimus and prednisone with additional use of MMF in 4 ( Table 2) .
Sirolimus was used in 2 additional patients (week 20 in pt 3 and week 28 in pt 21) as part of their maintenance immunosuppressive regimen.
| Viral immune reconstitution in the absence of infection posttransplant
To investigate the impact of posttransplant immunosuppression on cellular immunity, we prospectively tracked immunosuppression 
Immunosuppression reduction
Patients discontinuing prednisone by 6 months, n (%)
(81)
Average tacrolimus trough ng/mL, mean ± SEM Month 1 9.8 ± 0.6
Month 6
7.0 ± 0.8
Month 12
5.5 ± 0.8
Acute cellular rejection (ACR) during study period, n (%) 6 (37)
Median time to ACR, median months posttransplant (range) 7 (1-10)
TA B L E 2 Immunosuppressive characteristics and allograft outcomes in transplanted cohort
| Viral immune reconstitution in patients with active infections posttransplant
We next wanted to evaluate the impact of immunosuppression on virus-directed T cell immunity during 14 posttransplant viral infections/reactivations (Table 3) . In order to examine T cell dynamics during active infection, following identification of a new infection, we increased the frequency of blood collections to weekly and correlated changes in T cell levels with viral load levels (measured by quantitative polymerase chain reaction) and immunosuppression. Patients were further stratified based on whether infections were primary (de novo)
infections (CMV -n = 3; EBV -n = 4; HHV6 -n = 1) or reflected viral reactivations/secondary exposures (CMV -n = 2; EBV -n = 3;
AdV -n = 1). (Table S2 ).
| Primary infections
| D ISCUSS I ON
In this study, we prospectively monitored T cell immunity to a range We studied virus-specific immunity in pediatric liver transplant recipients for 2 reasons: (1) the broad age range allowed us to measure both primary (de novo) and secondary T cell responses in vivo, and (2) the "high-dose antigen effect," which may "exhaust" the recipient's immune system. 29 Together, these features permit a lower net state of immunosuppression than possible in other organ transplant recipients (eg, heart or lung), and allowed immunosuppression reduction as a feasible and safe strategy to manage viral infections in our cohort. colleagues also showed that development of T cell immunity to BK virus was associated with resolution of BK nephropathy. 32 Though our study of T cell immunity in pediatric liver transplant recipients was limited by factors including the small cohort size, the relatively low overall incidence of viral infections/reactivation, and the concurrent use of antiviral therapy in some patients, we nevertheless were able to show a correlation between functional virus-specific T cells and viral control consistent with other published work. [33] [34] [35] [36] Furthermore, this study is the first to explore cellular immunity to a broad spectrum of clinically problematic viruses in pediatric SOT recipients.
Our observations in this study of viral control associated with T cell expansion directed toward a broad range of viruses lends consideration for adoptive transfer of virus-specific T cells as a means of restoring antiviral immunity in SOT recipients where such endogenous activity is absent. Further supporting this notion are prior reports of adoptive T cell therapy to treat refractory viral infections (predominantly EBV) in SOT recipients. 37 Haque and colleagues administered partially HLA-matched EBV-specific VSTs generated from healthy third-party donors to 31 adult SOT recipients with refractory EBV-PTLD and established that this strategy was safe (no infusion-related toxicity or allograft rejection) and effective (52% response rate at 6 months). 38 More recently, Prockop and colleagues reported a similar 54% response rate in 13 SOT recipients with rituximab-resistant EBV-PTLD who received partially HLAmatched EBV-VSTs. 39 In the future, incorporation of prospective immune monitoring may provide better guidance in discriminating patients who can naturally control viral infections versus those who 
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